Skip to main content

Advertisement

Table 1 Comparison of RECIST 1.1, iRECIST, PERCIST, and iPERCIST criteria for immunotherapy evaluation

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

  RECIST 1.1 iRECIST PERCIST iPERCIST
Complete response Disappearance of all target and non-target lesions nodes, must regress to < 10 mm in the short axis Complete resolution of FDG uptake within the target lesion
Partial response ≥ 30% decrease in tumor burden compared to baseline (largest diameter in axial plane) ≥ 30% decrease in the target tumor FDG SULpeak
Stable disease Neither partial response, complete response nor progressive disease Neither partial response, complete response nor progressive disease
Disease progression ≥ 20% + 5 mm absolute increase in tumor burden compared with nadir. Appearance of new lesions or progression of non-target lesions ≥ 20% + 5 mm absolute increase in tumor burden compared with nadir. Appearance of new lesions or progression of non-target lesions. (iUPD)
Need to be confirmed 4–8 weeks later (iCPD); if progression is followed by tumor shrinkage, the bar is reset.
Clinical stability is considered when deciding whether treatment is continued after iUPD
≥ 30% increase in FDG SULpeak or advent of new 18F-FDG-avid lesions ≥ 30% increase in FDG SULpeak or advent of new 18F-FDG-avid lesions (UPMD)
Need to be confirmed by a second PET at 4–8 weeks later (CPMD); if progression is followed by PMR or SMD, the bar is reset.
Clinical stability is considered when deciding whether treatment is continued after UPMD
  1. RECIST Response Evaluation Criteria in Solid Tumors, iRECIST Immune RECIST, PERCIST PET Response Criteria in Solid Tumors, iPERCIST Immune PERCIST, FDG fluorodeoxyglucose, iCPD immune confirmed progressive disease, iUPD immune unconfirmed progressive disease, UPMD unconfirmed progressive metabolic disease, CPMD confirmed progressive metabolic disease, PMR partial metabolic response, SMD stable metabolic disease